Objective:

To evaluate the long-term efficacy and safety of romiplostim in patients with persistent thrombocytopenia following chemotherapy.

Approach:

• Study Design: An open-label, randomized Phase 2 trial compared romiplostim with standard of care in patients with solid tumors and persistent CIT.
• Patient Selection: Eligible patients had persistent CIT for at least 4 weeks despite chemotherapy dose reduction or delay.
• Outcome Measures: Primary outcomes included recovery of platelet counts and incidence of chemotherapy dose modifications or delays.

Key Findings:

• 93% of patients receiving romiplostim achieved platelet recovery within 3 weeks compared to 12% in the placebo group.
• Only 6.8% of patients on romiplostim experienced further chemotherapy reductions or delays due to CIT.
• Romiplostim treatment was effective and safe over the long term, with no evidence of resistance or increased thrombosis risk.

Interpretation:

The findings suggest that romiplostim effectively corrects persistent CIT and helps maintain chemotherapy dose intensity.

Limitations:

• Previous studies did not assess the impact of platelet count improvement on overall survival.
• Design of CIT trials focused on short-term hematologic endpoints rather than long-term survival outcomes.

Conclusion:

Romiplostim shows promise in managing persistent CIT, allowing for better maintenance of chemotherapy dose intensity.

Sources:

• National Comprehensive Cancer Network (NCCN) Guidelines
• International Society on Thrombosis and Hemostasis (ISTH) Guidance